In Re Namenda Direct Purchaser Antitrust Litigation, No. 1:2015cv07488 - Document 355 (S.D.N.Y. 2017)

Court Description: MEMORANDUM DECISION AND ORDER ADOPTING IN PART AND DECLINING TO ADOPT IN PART THE RECOMMENDATION OF MAGISTRATE JUDGE JAMES C. FRANCIS IV (DKT. NO. 335) for 308 Motion to Disqualify filed by Teva Pharmaceuticals USA, Inc., 269 Motion to Disqu alify filed by Forest Laboratories, Inc., Forest Laboratories Holdings Ltd., Forest Laboratories LLC, Actavis, plc, 335 Report and Recommendations. Defendants' motion to disqualify Dr. Lon Schneider (Dkt. No. 269) is DENIED. Teva 9;s motion to disqualify Ms. Jaskot (Dkt. No. 308) is GRANTED. The Clerk of the Court is directed to remove Dkt. Nos. 269 and 308 from the Court's list of pending motions. The Court thanks Magistrate Judge Francis for his diligent management of this case throughout its contentious pre-trial phase. (Signed by Judge Colleen McMahon on 8/21/17) (yv) Modified on 8/22/2017 (yv).

Download PDF
In Re Namenda Direct Purchaser Antitrust Litigation Doc. 355 Dockets.Justia.com

Some case metadata and case summaries were written with the help of AI, which can produce inaccuracies. You should read the full case before relying on it for legal research purposes.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.